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Novel Insights Into
Beta-Blocker Therapy
for Long QT Syndromes*
James P. Daubert, MD,†‡
Augustus O. Grant, MD, PHD,†§
Kent R. Nilsson, JR, MD†§
urham, North Carolina
The congenital long QT syndromes (LQTS [cumulative
incidence 1:2,000]) are individually distinct but exhibit a
common phenotype of QT-interval prolongation and sud-
den death risk. Potassium channel mutations, KCNQ1
(LQTS1) and KCNH2 (LQTS2), account for approxi-
mately 60% of cases. Beta-blockers have long been the
mainstay of therapy, dramatically reducing syncope and
death (1). Pharmacologically, beta-blockers blunt beta-
adrenergic receptor-mediated sympathetic stimulation, but
have varying half-lives and extracardiac effects contingent
upon beta-isoform specificity and lipophilicity (Table 1).
See page 2092
Although retrospective, several prior studies have compared the
efficacy of different beta-blockers in treating LQTS (Table 2)
(2–6). In this issue of the Journal, Chockalingham et al. (7)
resent a compelling argument that the pharmacologic
ifferences among 3 commonly prescribed beta-blockers—
ropranolol, nadolol, and metoprolol—significantly impact
rrhythmic risk in genotype confirmed LQTS1 and LQTS2
7). A multicenter cohort of 382 patients treated with
eta-blockers was assembled. The primary composite end-
oint included abrupt syncope, near drowning, seizure
pisodes, or aborted cardiac arrest. The investigators found
hat: 1) propranolol shortened QTc more than nadolol or
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Pharmaceutical.etoprolol; 2) QTc shortening inversely correlated with
ardiac events; and 3) metoprolol protected less than pro-
ranolol or nadolol.
First, the researchers compared the QTc before beta-
locker with on-therapy QTc. The propensity for propran-
lol to shorten the QTc was most evident for baseline QTc
xceeding 480 ms. The QTc shortening did not appear
rtifactual owing to an imperfect correction formula, as rate
lowed to a similar degree with each beta-blocker. To
onfirm differential QTc shortening, they exploited the
ransition of 14 patients (11 LQTS1 and 3 LQTS2) from
ropranolol to metoprolol. After switching, QTc increased
rom 447  20 ms to 464  39 ms. Notably, because the
herapy transition occurred at 11 years and the comparison
ropranolol ECG was recorded several years earlier, interim
ormonal changes could be operative (8). Data are limited
egarding differential QTc effects of beta-blockers in
QTS. In 1 small mechanistic study, propranolol did not
horten QTc under baseline conditions (9). However, body
urface electrode recordings uncovered favorable changes in
patial and transmural dispersion of repolarization;
ropranolol-mediated QTc shortening was noted during
pinephrine infusion. Further reinforcing the limitation of
sing QTc alone for arrhythmic risk, and the complexity of
rrhythmia occurrence in LQTS, is the observation that
omponents of the T wave can occur with adrenergic
timulation or blockade (10).
Second, Chockalingham et al. (7) observed that QTc
hortening was inversely proportional to cardiac events.
his observation supports a previous observation made by
oss et al. (1) in LQTS patients; they found that patients
nitiated on beta-blocker therapy who had a reduction in
Tc tended to have a favorable outcome. The inverse
elationship between QTc and sudden cardiac death has also
een observed in non-LQTS patients with coronary artery
isease (11), further underscoring the role that transmural
ispersion of repolarization has in ventricular arrhythmias.
he ability to directly modify QTc and seemingly decrease
he risk of cardiac events focuses attention on whether other
gents that can shorten QTc, particularly in LQT3 (12),
ould reduce arrhythmic events. In addition, one could
ypothesize that manipulation of QT might have benefits in
ther situations, such as ischemic heart disease. Clearly, our
nderstanding is incomplete, in that nadolol did not shorten
Comparison of Beta-BlockersStudied in Long QT SyndromeTable 1 Comparison f Beta-BlockersStudied in Long QT Syndrome
Drug
-1
Selective? Lipophilicity* I-Na Block? Half-Life (h)
Propranolol No Highly Yes, late,
non-inactivating
5–7†
Nadolol No Minimal Yes, peak current 14–24
Metoprolol Yes Moderate No 3–7*Correlates with ability to cross blood-brain barrier. †Half-life of principal metabolite,
4-hydroxypropranolol.
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favorable outcomes, unlike metoprolol.
Third, Chockalingham et al. (7) found metoprolol infe-
rior to both propranolol and nadolol for the prevention of
cardiac events in patients with LQTS1 and LQTS2. At 10
years of follow-up, patients receiving either propranolol or
nadolol had an event-free survival of 91% as compared with
60% on metoprolol. Although retrospective, these results do
argue against the use of metoprolol and in favor of either
nadolol or propranolol in the treatment of LQTS. In
addition, because considerations of convenience and com-
pliance drove the transition from short-acting propranolol
to metoprolol, such changes must not be undertaken lightly.
In this regard, nadolol had excellent efficacy and possesses
pharmacokinetics compatible with once-daily dosing (Table 1).
As 99% of propranolol-treated patients used the short-
acting preparation, it is not clear whether extended-release
propranolol is an acceptable alternative.
While the Chockalingham et al. (7) deserve recognition
for their important observations, several limitations must be
emphasized. First, owing to the nonrandomized nature of
this retrospective analysis, there were significant differences
in baseline clinical characteristics between the different
treatment groups, including sex, history of syncope, baseline
QTc, age at which therapy was started, and on-therapy
heart rate. Three other aspects of the patient population
need to be emphasized: 1) the baseline mean QTc for the
study population was 472 ms, indicating that a significant
proportion of the patient population (64%) had a normal or
borderline QTc; 2) only 27% of the study population had
had symptoms before therapy, roughly correlating with the
number of patients with a prolonged QTc; and 3) a
significant number of patients switched beta-blockers dur-
ing follow-up, an observation capitalized upon by the
investigators, as noted. Next, caution is needed in general-
izing about preferred therapy for LQTS, as LQT1, 2, and 3
(and other subtypes) represent multiple syndromes with
unique characteristics. Even within subtypes, risk and beta-
blocker benefit may vary by mutation site, type, and other
factors (5). For example, LQTS1 patients harboring C-loop
mutations appear to respond more favorably to beta-
tudies Evaluating and Comparing Beta-Blockers in Long QT SyndrTable 2 Studies Evaluating and Comparing Beta-Blockers in Lo
First Author (Ref. #) Genotype
Moss (1) LQTS 1, 2, 3 (n  860) QTc shortening associated with
Chathrath (6) LQTS 1, 2, 3 (n  28) Atenolol associated with adver
Vincent (2) LQTS 1 (n  216) No QTc shortening; beta-blocke
84% of experience with pro
Barsheshet (5) LQTS 1 (n  860) Beta-blockers more efficacious
Priori S (3) LQTS 1, 2, 3 (n  335) Beta-blockers more efficacious
Shimizu (9) LQTS 1, 2 (n  22) Propranolol reduced QTc durin
Goldenberg (4) LQTS 1, 2 Atenolol more effective in LQT
HR  hazard ratio; LQTS  long QT syndrome; QTc  corrected QT interval.blockers (5). Intriguingly, mutation of the sodium-channelblocker binding site can affect the ability of propranolol to
block sodium current (13).
In conclusion, Chockalingham et al. (7) provide some of the
most compelling evidence to date that “not all beta-blockers are
equal.” Although randomized trials are formidable involving
rare conditions like LQTS, additional data on differential
benefit of beta-blockers from registries would be helpful.
Moreover, these findings suggest the potential for reducing
sudden death by QTc modulation in common acquired con-
ditions exhibiting QTc prolongation and/or increased trans-
mural dispersion of refractoriness.
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